{
  "id": "CD013474.PUB2",
  "draft": "Does continuing treatment (maintenance therapy) after initial therapy improve survival or disease control for people with chronic lymphocytic leukaemia (CLL) compared with just observation?\n\nKey messages\n- Maintenance therapy does not seem to increase overall survival (how long people live), but it does lengthen progression‑free survival (the time before the disease gets worse).\n- The evidence mainly comes from anti‑CD20 antibodies (lab‑made proteins that target a marker on cancer cells) and lenalidomide (a medicine that modifies the immune system). Both increase overall side‑effects and serious (grade 3/4) side‑effects.\n- No studies have evaluated newer targeted drugs such as BTK inhibitors or BCL‑2 inhibitors, and information on quality of life is limited.\n\nWhat is chronic lymphocytic leukaemia and why might people need ongoing treatment?\nChronic lymphocytic leukaemia (CLL) is the most common adult blood cancer. It happens when a type of white blood cell called a lymphocyte grows uncontrollably and builds up in the blood, bone marrow and sometimes the spleen. CLL cannot be cured, and each round of standard (induction) therapy tends to shorten the time before the disease returns. Doctors therefore look for ways to keep the disease under control for longer after the first treatment. One approach is maintenance therapy – giving a lower‑dose or different drug after remission to deepen the response and delay relapse. Options include:\n- Anti‑CD20 monoclonal antibodies (e.g., rituximab, ofatumumab) – proteins that target the CD20 marker on cancer cells.\n- Immunomodulatory drugs such as lenalidomide – medicines that help the immune system fight the cancer.\n- Anti‑CD52 monoclonal antibodies (e.g., alemtuzumab) – proteins that target the CD52 marker.\n- Targeted oral inhibitors such as BTK inhibitors and BCL‑2 inhibitors – pills that block signals cancer cells need to survive.\nPeople who achieve remission after their first treatment can either be observed (watch‑and‑wait) or start one of these maintenance options.\n\nWhat did the review aim to discover about maintenance therapies for CLL?\nWe wanted to know whether maintenance treatments improve important outcomes for people with CLL and whether they are safe. Specifically, we compared five maintenance drugs – anti‑CD20 antibodies, immunomodulatory drugs, anti‑CD52 antibodies, BTK inhibitors and BCL‑2 inhibitors – with placebo or observation. We examined:\n- Overall survival (how long people live).\n- Progression‑free survival (how long the disease stays controlled).\n- Health‑related quality of life (how treatment affects daily well‑being).\n- Serious side‑effects (grade 3/4 adverse events), treatment‑related deaths, treatment discontinuation and any other adverse events.\n\nHow did we find and assess the evidence?\nWe searched CENTRAL, MEDLINE, Embase and trial registers in January 2022 for randomised controlled trials that compared any maintenance therapy with observation or another maintenance option. Two reviewers screened studies, extracted data and assessed risk of bias. We used the GRADE approach to rate confidence in the evidence for each outcome.\n\nWhat did we find?\nWe identified 11 randomised trials involving 2,393 people with CLL. Participants were followed for 1 to 6 years. The trials tested three maintenance strategies:\n- Anti‑CD20 antibodies (rituximab or ofatumumab) in seven trials (1,679 participants).\n- Lenalidomide in three trials (693 participants).\n- Alemtuzumab in one very small trial (21 participants).\nAnti‑CD20 maintenance probably makes little or no difference to overall survival, probably improves progression‑free survival, and may slightly raise both overall side‑effects and serious (grade 3/4) side‑effects. Lenalidomide maintenance probably makes little or no difference to overall survival, probably leads to a large improvement in progression‑free survival, probably raises serious side‑effects and treatment‑related deaths slightly, and probably increases overall side‑effects. Evidence for alemtuzumab maintenance is very uncertain, and we could not determine its effect on progression‑free survival. No trials evaluated newer targeted agents, and quality‑of‑life data were scarce.\n\nWhat are the limitations of the evidence?\nWe have moderate confidence in the evidence because many trials were small, some participants knew which treatment they received, and not all outcomes were reported. The evidence does not cover all patient groups or newer drugs.\n\nHow up‑to‑date is this review?\nThe searches were current to January 2022, so newer studies published after that date are not included.",
  "metrics": [
    {
      "linguistic_evaluation": {
        "words": {
          "value": 687,
          "rating": "within_limit",
          "direction": null,
          "feedback": null
        },
        "sentences": {
          "value": 35,
          "rating": "info",
          "direction": null,
          "feedback": null
        },
        "words_per_sentence": {
          "value": 19.62857142857143,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "passive_voice": {
          "value": 16,
          "rating": "P75",
          "direction": "lower_better",
          "feedback": null
        },
        "active_voice": {
          "value": 69,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "pronouns": {
          "value": 33,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "nominalization": {
          "value": 40,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 40.0 to <13.0 (median)"
        },
        "nouns": {
          "value": 210,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 210.0 to <116.0 (median)"
        },
        "flesch_reading_ease": {
          "value": 48.4980262008734,
          "rating": "P75",
          "direction": "higher_better",
          "feedback": null
        },
        "flesch_kincaid_grade": {
          "value": 11.37111083385319,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "automated_readability_index": {
          "value": 11.687473487211484,
          "rating": "P25",
          "direction": "lower_better",
          "feedback": null
        },
        "coleman_liau_index": {
          "value": 11.783871906841341,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "gunning_fog_index": {
          "value": 17.691312123102517,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "lix": {
          "value": 51.94298190892077,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "rix": {
          "value": 6.3428571428571425,
          "rating": "P50",
          "direction": "lower_better",
          "feedback": null
        },
        "smog_index": {
          "value": 15.529964086141668,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 15.5 to <12.1 (median)"
        },
        "dale_chall_readability": {
          "value": 8.535309311707218,
          "rating": "P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 8.5 to <7.7 (median)"
        },
        "complex_words_dc": {
          "value": 329,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 329.0 to <160.0 (median)"
        },
        "complex_words": {
          "value": 169,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 169.0 to <84.0 (median)"
        },
        "long_words": {
          "value": 222,
          "rating": "BEYOND_P90",
          "direction": "lower_better",
          "feedback": "Deviates from typical PLS patterns. Consider reducing from 222.0 to <122.0 (median)"
        }
      },
      "word_count_status": {
        "word_count": 687,
        "limit": 850,
        "status": "within_limit",
        "message": "Word count: 687 ✓ WITHIN LIMIT (≤850 words)"
      },
      "summary": {
        "P25_count": 3,
        "P50_count": 4,
        "P75_count": 4,
        "P90_count": 1,
        "P10_count": 0,
        "BEYOND_P90_count": 6,
        "BELOW_P10_count": 0,
        "total_evaluated": 18,
        "P25_percentage": 16.666666666666664,
        "P50_percentage": 22.22222222222222,
        "P75_percentage": 22.22222222222222,
        "P90_percentage": 5.555555555555555,
        "P10_percentage": 0,
        "BEYOND_P90_percentage": 33.33333333333333,
        "BELOW_P10_percentage": 0,
        "best_quartile_rate": 38.88888888888889,
        "overall_assessment": "MODERATE CONFORMITY WITH PLS PATTERNS"
      }
    }
  ],
  "evaluation": [
    {
      "grade": "NOT_APPROVED",
      "feedback": "The draft passes the required structural and factual checks, but several clarity problems would likely confuse patients:\n1. **Unexplained medical jargon** – terms like “grade 3/4 adverse events” and “moderate‑certainty evidence” are used without plain‑language definitions.\n2. **Overly dense sentence** – the sentence summarising anti‑CD20 results packs three separate messages into one long clause, making it hard to follow.\n3. **Nominal‑heavy, passive phrasing** – phrases such as “The evidence does not cover all patient groups or newer drugs” and “We have moderate confidence in the evidence because …” use nouns instead of clear verbs and create a passive tone.\n4. **Long, compound sentence in the limitations paragraph** – the sentence about confidence mixes several reasons together, reducing readability.\n5. **Technical description of the search** – the methods sentence is wordy and includes research‑specific terms that could be simplified.\nThese issues are reflected in the metric analysis (high nominalisation 40, high noun count 210, high SMOG 15.5, many complex words), indicating the text is more noun‑heavy and complex than typical PLS. Rewriting the highlighted sentences into shorter, active, plain‑language statements will bring the draft into line with Cochrane PLS style and improve patient comprehension.",
      "pls_evaluation_summary": "The PLS evaluation shows moderate overall conformity but notable deviations: nominalisation (40, BEYOND_P90), noun count (210, BEYOND_P90), SMOG index (15.5, BEYOND_P90), Dale‑Chall readability (8.5, P90), and high counts of complex and long words. These metrics confirm the draft is more noun‑heavy and complex than typical plain‑language summaries, supporting the need for the suggested clarity improvements."
    }
  ]
}